Moleculin Biotech CS (MBRX)

Jul 9, 2025, 8:35 AM EDT - 2 days ago

Moleculin Expands Phase 3 MIRACLE Clinical Trial into the Country of Georgia, Enrollment Update and Future Plans

Jun 26, 2025, 8:15 AM EDT - 15 days ago

Top 3 Health Care Stocks You'll Regret Missing This Quarter

CPRX

Jun 20, 2025, 9:20 AM EDT - 21 days ago

Moleculin Announces $5.9 Million Public Offering

Jun 18, 2025, 7:45 AM EDT - 23 days ago

Moleculin Participates in Virtual Investor “What This Means” Segment

Jun 18, 2025, 7:30 AM EDT - 23 days ago

Moleculin Receives Positive FDA Feedback on Pediatric Study Plan for Annamycin in Children with R/R AML

Jun 5, 2025, 8:00 AM EDT - 5 weeks ago

Moleculin Releases On-Demand KOL Webcast to Discuss Data from its Phase 1B/2 Study of Annamycin for the Treatment of Soft Tissue Sarcoma (STS) Lung Metastases (MB-107)

Jun 4, 2025, 8:45 AM EDT - 5 weeks ago

Moleculin Reports Positive Topline Efficacy Results from U.S. Phase 1B/2 Clinical Trial Evaluating Annamycin for the Treatment of Soft Tissue Sarcoma Lung Metastases (MB-107)

May 14, 2025, 12:20 PM EDT - 2 months ago

Moleculin Biotech, Inc. (MBRX) Q1 2025 Earnings Call Transcript

May 14, 2025, 7:30 AM EDT - 2 months ago

Moleculin Reports First Quarter 2025 Financial Results and Provides Corporate Update

May 12, 2025, 8:40 AM EDT - 2 months ago

Moleculin Receives European Medicines Agency Approval to Expand Phase 3 MIRACLE Clinical Trial

May 7, 2025, 9:00 AM EDT - 2 months ago

Moleculin to Report First Quarter 2025 Financial Results on May 13, 2025 and Host Conference Call and Webcast

May 6, 2025, 9:00 AM EDT - 2 months ago

Moleculin Announces World Health Organization Approval of “naxtarubicin” as International Non-Proprietary Name for Annamycin

May 5, 2025, 8:45 AM EDT - 2 months ago

Moleculin Bolsters Annamycin Intellectual Property Portfolio with Granting of Two New U.S. Patents

Apr 29, 2025, 8:35 AM EDT - 2 months ago

Moleculin Announces New Pre-Clinical Data for Annamycin Demonstrating Market Expansion Potential Including Treatment for Pancreatic Cancer

Apr 17, 2025, 8:30 AM EDT - 3 months ago

Moleculin Announces Acceptance of Abstract to be Presented at the American Association for Cancer Research (AACR) Annual Meeting 2025

Apr 1, 2025, 8:30 AM EDT - 3 months ago

Moleculin Doses First Patient in Pivotal, Adaptive Phase 3 MIRACLE Trial

Mar 24, 2025, 10:50 AM EDT - 3 months ago

Moleculin Biotech, Inc. (MBRX) Q4 2024 Earnings Call Transcript

Mar 24, 2025, 7:05 AM EDT - 3 months ago

Moleculin Reports Full Year 2024 Financial Results and Provides Corporate Update

Mar 19, 2025, 8:05 AM EDT - 4 months ago

Moleculin to Report Full Year 2024 Financial Results on March 21, 2025 and Host Conference Call and Webcast

Mar 11, 2025, 8:45 AM EDT - 4 months ago

Moleculin Biotech, Inc. Participates in the Virtual Investor "Top 5 for '25" On-Demand Conference

Mar 10, 2025, 8:45 AM EDT - 4 months ago

Moleculin to Present at the 37th Annual ROTH Conference

Mar 6, 2025, 8:30 AM EST - 4 months ago

Moleculin Announces Additional Annamycin Patent Allowances to Enhance Global Exclusivity

Mar 3, 2025, 8:30 AM EST - 4 months ago

Moleculin Abstract Accepted for Poster Presentation at the Acute Leukemias XIX (ISALXIX) International Symposium

Feb 25, 2025, 12:35 PM EST - 4 months ago

Moleculin Announces Pricing of $3.5 Million Registered Direct Offering and Concurrent Private Placement Priced At The Market Under Nasdaq Rules

Feb 13, 2025, 1:19 PM EST - 5 months ago

Why Is Blood Cancer Focused Moleculin Biotech Stock Trading More Than 400% On Thursday?

Feb 13, 2025, 1:05 PM EST - 5 months ago

Moleculin Announces Exercise of Warrants for $5.8 Million Gross Proceeds

Feb 13, 2025, 9:25 AM EST - 5 months ago

Moleculin Receives Positive FDA Guidance for Acceleration of its Registration-Enabling MIRACLE Trial for R/R Acute Myeloid Leukemia (AML)

Feb 11, 2025, 8:40 AM EST - 5 months ago

Moleculin Receives First Country Approval in Europe to Begin Recruiting for the MIRACLE Phase 3 R/R Acute Myeloid Leukemia (AML) Pivotal Trial

Jan 27, 2025, 8:30 AM EST - 5 months ago

Moleculin Participates in Virtual Investor "What This Means" Segment

Jan 8, 2025, 8:30 AM EST - 6 months ago

Moleculin Highlights Development Progress of Annamycin, Phase 2 Data Outperforms Billion-Dollar Assets in AML, Phase 3 Data Readouts in 2025 & 2026

Dec 11, 2024, 8:00 AM EST - 7 months ago

Moleculin Announces Online Publication of Preclinical Data Demonstrating Significant Activity of Annamycin in Venetoclax Resistant AML Model

Nov 18, 2024, 8:15 AM EST - 8 months ago

New Findings Show Moleculin's Annamycin Overcomes Resistance to Venetoclax in AML

Nov 14, 2024, 8:15 AM EST - 8 months ago

Moleculin Accelerates Planned Unblinded Data Readout for MIRACLE Phase 3 R/R Acute Myeloid Leukemia (AML) Pivotal Trial to H2 2025

Nov 12, 2024, 8:00 AM EST - 8 months ago

Moleculin Receives Institutional Review Board Approval for MIRACLE Phase 3 Pivotal Trial of Annamycin in Combination with Cytarabine for the Treatment of R/R Acute Myeloid Leukemia (AML)

Nov 11, 2024, 11:17 AM EST - 8 months ago

Moleculin Biotech, Inc. (MBRX) Q3 2024 Earnings Call Transcript

Nov 11, 2024, 7:05 AM EST - 8 months ago

Moleculin Reports Third Quarter 2024 Financial Results and Provides Corporate Update

Nov 5, 2024, 9:00 AM EST - 8 months ago

Moleculin to Report Third Quarter 2024 Financial Results on November 8, 2024 and Host Conference Call and Webcast

Nov 4, 2024, 8:30 AM EST - 8 months ago

Moleculin Appoints Leading Expert in Pancreatic Cancer to its Scientific Advisory Board to Support Development of Annamycin

Oct 17, 2024, 8:40 AM EDT - 9 months ago

Transcript from Moleculin's Recent Virtual Acute Myeloid Leukemia KOL Event Now Available

Oct 7, 2024, 8:30 AM EDT - 9 months ago

Moleculin to Host Virtual Acute Myeloid Leukemia KOL Event on October 14, 2024

Oct 4, 2024, 9:00 AM EDT - 10 months ago

Moleculin to Present at Two Upcoming Investor Conferences

Sep 23, 2024, 8:00 AM EDT - 10 months ago

Moleculin Announces Positive In Vivo Efficacy Data of Annamycin in Orthotopic and Experimental Lung Metastatic Models of Sarcoma

Sep 16, 2024, 8:30 AM EDT - 10 months ago

Moleculin Participates in Virtual Investor "What this Means" Segment

Sep 9, 2024, 8:15 AM EDT - 10 months ago

Moleculin Announces First Patients Treated in Phase 2 Clinical Trial of STAT3 Inhibitor in Combination with Radiation for the Treatment of Glioblastoma

Sep 3, 2024, 9:15 AM EDT - 11 months ago

Moleculin to Present at the H.C. Wainwright 26th Annual Global Investment Conference

Aug 26, 2024, 8:30 AM EDT - 11 months ago

Moleculin to Present at LIVE! with Webull Corporate Connect: Healthcare Investment Webinar

Aug 19, 2024, 4:05 PM EDT - 11 months ago

Moleculin Announces Closing of up to $16.5 Million Public Offering

Aug 14, 2024, 8:05 AM EDT - 11 months ago

Moleculin Reports Second Quarter 2024 Financial Results and Provides Corporate Update

Aug 5, 2024, 9:05 AM EDT - 1 year ago

Moleculin to Host Webcast Presentation to Discuss Recently Announced Plans for MIRACLE Phase 3 Pivotal Trial Tuesday, August 6, 2024 at 8:30 AM ET

Aug 1, 2024, 8:30 AM EDT - 1 year ago

Moleculin Announces Plans for MIRACLE Phase 3 Pivotal Trial